Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Journal Information
Full Title: Pharm Res
Abbreviation: Pharm Res
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Conflict of InterestThe authors are employees of and may own shares/stock option in Pfizer, Inc. Conflict of Interest The authors are employees of and may own shares/stock option in Pfizer, Inc."
Funding Disclosure
Evidence found in paper:
"Funding This study was sponsored by Pfizer Inc."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025